CHEMILY, LLC — Department of Health and Human Services SBIR Phase I: 300

Description

Project summary abstract This proposal is to synthesize and commercialize Fmoc protected glycoamino acidsGAAsin large scaleGlycoproteins have been reported to exhibit a pivotal role in processes as diverse as fertilizationneuronal developmenthormone activitiesimmune surveillanceand inflammatory responsesGAAs are the brick to build all glycopeptides and glycoproteinsThe synthesis of GAAs requires sophisticated protection deprotection and activation strategies that is time consumingGlycoscientists have faced many challenges with obtaining pure compounds in sufficient quantitiesDue to glycoscience s reliance on GAAsthere is an urgent need for a production pipeline to provide these essential building blocksThe goal of ourLarge scale preparation of Glycoamino acidsGAAsfor expanded glycopeptides and glycoproteins synthesisis to meet this need and commercialize a stableaffordable and diverse supply of GAAs to drive advances in glycoscienceThe availability and cost of these GAAs are the keys for advancing glycoscience for many fields of biomedical and materials sciencesIn this proposed SBIR Phase IChemily will develop the latest synthetic strategy and route to produce theGAAs ong scalesChemily will also set up and usetoL reactors to produce some of the high demanding GAAs on kg scaleChemily should be able to produce some of the GAAs around $gThis will open the access of many synthetic glycopeptides and glycoproteinsIn summarythis project should make such a dream come truescientists can have affordable access to glycopeptides as they have these GAAs building blocksA stable supply of GAAs will facilitate experiments that advance our understanding of cell surface markerscell recognitionand protein carbohydrate interactionsIn turnsynthetic glycopeptides offer a unique frontier for research in glycobiology and proteomics as well as for drug discovery andampdevelopmentdrug delivery targetingdiagnostics developmentand biotechnological applications Project narrative The health relevance of this project is linked to developments in glycan technologydue the fundamental nature of glycoamino acids as building blocks for the glycopeptides and glycoproteinA stable supply of these building blocks will facilitate experiments that advance our understanding of cell surface markerscell recognitionand protein carbohydrate interactionsIn turnsynthetic glycopeptides offer a unique frontier for research in glycobiology and proteomics as well as for drug discovery andampdevelopmentdrug delivery targetingdiagnostics developmentand biotechnological applications